NEW YORK, Feb. 10, 2022 /PRNewswire/ -- The stroke therapeutics market is estimated to grow by USD 1.54 billion from 2020 to 2025, and the market's growth is anticipated to accelerate at a CAGR of 5%.
Factors such as high-risk factors for stroke and the development of novel therapies are supporting the stroke therapeutics market growth positively.
Our research report on "Stroke Therapeutics Market by Type and Geography - Forecast and Analysis 2021-2025" has extensively covered factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the market share during the forecast period.
Stroke Therapeutics Market Report Key Highlights
Stroke Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.00% |
Market growth 2021-2025 |
$ 1.54 billion |
Market structure |
Fragmented |
YoY growth (%) |
4.68 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 40% |
Key consumer countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Pfizer Inc., and Sanofi SA |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Do reach out to our analysts for more customized reports as per needs. Speak to our Analyst now!
Stroke Therapeutics Market Trend
Novel therapies such as the stem cell therapies are gaining significant traction in the market. With the rising numbers of chronic conditions fueling the high prevalence of strokes, the need for safe and innovative novel therapies has increased in the recent years. Several companies are launching novel therapies and drugs for the treatment of strokes. For instance, Athersys is developing MultiStem. It is a cell therapy regenerative medicine product currently in Phase III clinical development for the treatment of ischemic strokes. For instance, Athersys is developing MultiStem. It is a cell therapy regenerative medicine product currently in Phase III clinical development for the treatment of ischemic strokes.
Stroke Therapeutics Market Challenge
The high level of genericization in the market will be a major challenge for the stroke therapeutics market during the forecast period. There has been a growing dominance of low-cost generics likely to affect the sales of the drugs. Pharmaceuticals companies are entering the market with low-cost generics owing to the patent expiry of several branded drugs. For instance, after CRESTOR (rosuvastatin calcium from AstraZeneca) lost its patent exclusivity, several companies received approvals for generic versions of the drug.
Get free sample for extensive insights on key market Drivers, Trends, and Challenges influencing the stroke therapeutics market.
Key Market Vendors Insights
The stroke therapeutics market is fragmented, and the vendors are deploying growth strategies such as forming strategic alliances and acquisitions to compete in the market.
Some of the key market vendors are:
For more detailed highlights on products offerings and the growth strategies adopted by other vendors, Download free sample report
The ischemic stroke type segment held the largest stroke therapeutics market share in 2020. The growth of this segment can be attributed to the robust development of the drug pipeline for this type of stroke. High-risk factors, such as obesity, atherosclerosis, hypertension, and old age, are the major contributors to the growth of the segment during the forecast period. These conditions have increased the prevalence of strokes, in turn, driving the growth of this segment.
Regional Market Analysis
North America emerged as the largest revenue-generating regional segment of stroke therapeutics market. 40% of the market's growth will originate from North America during the forecast period. The high prevalence of the disease and recent product approvals will facilitate the stroke therapeutics market growth in North America over the forecast period. The US is the key market for stroke therapeutics in North America. The recent approval of drugs for strokes is also expected to contribute to the growth of the market in the region. For instance, in 2020, AstraZeneca's Brilinta (ticagrelor) was approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide. US, Germany, UK, China, and Japan will emerge as some of the key revenue-contributing economies to the stroke therapeutics market.
Request our free sample for additional highlights and key segments that are expected to impact the market during the forecast period.
Related Reports
Acute Ischemic Stroke Therapeutics Market by Type and Geography - Forecast and Analysis 2020-2024- The acute ischemic stroke therapeutics market size has the potential to grow by USD 1.22 billion from 2019 to 2024, and the market's growth momentum will accelerate at a CAGR of 5.39%. Download Exclusive Free Sample Report
Induced Pluripotent Stem Cells Production Market by End-user and Geography - Forecast and Analysis 2022-2026- The induced pluripotent stem cells production market has the potential to grow by USD 1.55 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 11.39%. Download Exclusive Free Sample Report
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis are focused on emerging market trends and actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
Share this article